+++
title = "Hematopathology, 2nd edition by Jaffe, Arber, Campo, Harris, and Quintanilla-Martinez"
author = ["Cameron Smith"]
lastmod = 2020-09-20T17:34:38-04:00
slug = "Hematopathology,_2nd_edition_by_Jaffe,_Arber,_Campo,_Harris,_and_Quintanilla-Martinez"
draft = false
+++

## Hematologic malignancies by incidence {#hematologic-malignancies-by-incidence}


### Lymphoid malignancies {#lymphoid-malignancies}

<!--list-separator-->

-  \![Harrison's figure on the incidence of lymphomas](<https://lh3.googleusercontent.com/3Meil5skJPNRjS5B8Jd4U9NhumUcwSvmrcO82RjuhQKuShYS3Y8CYRpTL8y3pUMI%5FTdnx8FPj01vEfOVsyqiIiC2TjVEOs0OtaKuvLjsboBVHU69hePxzBexdhODl09MXs7AKUc3PdI=w1186-h741-no>)

<!--list-separator-->

-  19.3 NHL DLBCL ~ .624\*.31 ~19.3%

<!--list-separator-->

-  16.0 Plasma cell disorders (multiple myeloma) ~16%

<!--list-separator-->

-  13.7 NHL Follicular lymphoma ~ .624\*.22 ~13.7%

<!--list-separator-->

-  09.0 CLL ~9%

<!--list-separator-->

-  08.2 HL ~8.2%

<!--list-separator-->

-  04.7 NHL MALT lymphoma .624\*.076 ~4.7%

<!--list-separator-->

-  04.7 NHL Mature T-cell lymphoma .624\*.076 ~4.7%

<!--list-separator-->

-  04.2 NHL Small lymphocytic lymphoma .624\*.067 ~4.2%

<!--list-separator-->

-  03.8 ALL ~3.8%

<!--list-separator-->

-  03.7 Mantle cell lymphoma 0.624\*.06 ~ 3.7%


### Plasma cell dyscrasias {#plasma-cell-dyscrasias}

<!--list-separator-->

-  Multiple myeloma \* 139,000


### Lymphomas {#lymphomas}

<!--list-separator-->

-  NHL \* 461,000

<!--list-separator-->

-  Hodgkin lymphoma \* 73,000


### Leukemias {#leukemias}

<!--list-separator-->

-  Other leukemias \* 150,000

<!--list-separator-->

-  CLL \* 105,000

<!--list-separator-->

-  AML \* 103,000

<!--list-separator-->

-  ALL \* 76,000

<!--list-separator-->

-  CML \* 32,000


## I. Technical aspects {#i-dot-technical-aspects}


### 1. Processing of the lymph node biopsy specimen {#1-dot-processing-of-the-lymph-node-biopsy-specimen}

<!--list-separator-->

-  Instructions for the surgeon

<!--list-separator-->

-  Gross processing of the lymph node biopsy by the pathologist

    <!--list-separator-->

    -  Gross examination

    <!--list-separator-->

    -  Frozen sections

    <!--list-separator-->

    -  Cytologic preparations

    <!--list-separator-->

    -  Sectioning

    <!--list-separator-->

    -  Fixation

    <!--list-separator-->

    -  Contribution of the histotechnologist

<!--list-separator-->

-  Routine histologic, histochemical, and special stains

<!--list-separator-->

-  Choice of ancillary studies

<!--list-separator-->

-  Reporting the lymph node biopsy


### 2. Fine needle aspiration of lymph nodes {#2-dot-fine-needle-aspiration-of-lymph-nodes}


### 3. Collection, processing, and examination of bone marrow specimens {#3-dot-collection-processing-and-examination-of-bone-marrow-specimens}


### 4. Immunohistochemistry for the hematopathology laboratory {#4-dot-immunohistochemistry-for-the-hematopathology-laboratory}


### 5. [flow cytometry]({{< relref "flow_cytometry" >}}) {#5-dot-flow-cytometry--flow-cytometry-dot-md}


### 6. Molecular diagnosis in hematopathology {#6-dot-molecular-diagnosis-in-hematopathology}


### 7. Important chromosomal aberrations in hematologic neoplasms and key techniques to diagnose them {#7-dot-important-chromosomal-aberrations-in-hematologic-neoplasms-and-key-techniques-to-diagnose-them}


## II. Normal and reactive conditions of hematopoietic tissues {#ii-dot-normal-and-reactive-conditions-of-hematopoietic-tissues}


### 8. Normal lymphoid organs and tissues {#8-dot-normal-lymphoid-organs-and-tissues}


### 9. Reactive lymphadenopathies {#9-dot-reactive-lymphadenopathies}

<!--list-separator-->

-  Follicular and nodular patterns

<!--list-separator-->

-  Predominantly sinus pattern

<!--list-separator-->

-  Interfollicular or mixed patterns

    <!--list-separator-->

    -  Paracortical hyperplasia and dermatopathic reaction

    <!--list-separator-->

    -  Granulomatous lymphadenitis

    <!--list-separator-->

    -  Immunoglobulin G4-related lymphadenopathy

    <!--list-separator-->

    -  Kimura's disease

    <!--list-separator-->

    -  Toxoplasmic lymphadenitis

    <!--list-separator-->

    -  Systemic lupus erythematosus

    <!--list-separator-->

    -  Kikuchi's lymphadenitis (histiocytic necrotizing lymphadenitis)

        <!--list-separator-->

        -  Epidemiology

            <!--list-separator-->

            -  First described in Japan in 1972

            <!--list-separator-->

            -  Predominantly affects young adults

            <!--list-separator-->

            -  Young women of Asian descent are commonly affected

        <!--list-separator-->

        -  Clinical presentation

            <!--list-separator-->

            -  cervical lymphadenopathy

            <!--list-separator-->

            -  sometimes with fever and leukopenia

        <!--list-separator-->

        -  Stages

            <!--list-separator-->

            -  Proliferative stage

                <!--list-separator-->

                -  numerous immunoblasts

                <!--list-separator-->

                -  large mononuclear cells including histiocytes with curved nuclei

                <!--list-separator-->

                -  aggregates of plasmacytoid dendritic cells with interspersed Karyorrhectic bodies

                    <!--list-separator-->

                    -  necrosis may appear to have begun within these aggregates or nests

            <!--list-separator-->

            -  Necrotizing stage

                <!--list-separator-->

                -  neutrophil-depleted patchy areas of necrosis within the paracortex containing abundant karyrrhectic nuclear debris and surrounded by a mixture of mononuclear cells (as in the proliferative type)

                <!--list-separator-->

                -  karyorrhectic debris is both extracellular and phagocytized by histiocytes

            <!--list-separator-->

            -  Xanthomatous stage

                <!--list-separator-->

                -  foamy histiocytes and fewer immunoblasts

                <!--list-separator-->

                -  necrosis may be absent

                <!--list-separator-->

                -  thought to represent the healing phase

        <!--list-separator-->

        -  Diagnostic criteria

            <!--list-separator-->

            -  Histologic features

                <!--list-separator-->

                -  paracortical clusters of plasmacytoid dendritic cells

                <!--list-separator-->

                -  karyorrhectic bodies

                <!--list-separator-->

                -  crescentic histiocytes

                <!--list-separator-->

                -  immunoblasts scattered among small lymphocytes

                <!--list-separator-->

                -  proliferation of high endothelial venules

            <!--list-separator-->

            -  Immunophenotype

                <!--list-separator-->

                -  CD8+ T cells outnumber CD4+ T cells

                <!--list-separator-->

                -  CD123/68/4/43+ plasmacytoid dendritic cells

                <!--list-separator-->

                -  CD68+ and MPO+ histiocytes

                <!--list-separator-->

                -  rare B cells

        <!--list-separator-->

        -  Differential diagnosis

            <!--list-separator-->

            -  Lupus lymphadenitis

                <!--list-separator-->

                -  Extensive necrosis, hematoxylin bodies, and plasma cells or neutrophils favor SLE

                <!--list-separator-->

                -  Kikuchi's patients usually lack ANA

            <!--list-separator-->

            -  Non-Hodgkin's lymphoma

    <!--list-separator-->

    -  Kawasaki's disease (mucocutaneous lymph node syndrome)

    <!--list-separator-->

    -  Inflammatory pseudotumor

    <!--list-separator-->

    -  Bacillary angiomatosis

<!--list-separator-->

-  Diffuse pattern


### 10. Normal bone marrow {#10-dot-normal-bone-marrow}

<!--list-separator-->

-  Hematopoiesis

    <!--list-separator-->

    -  Erythropoiesis

    <!--list-separator-->

    -  Granulopoiesis

    <!--list-separator-->

    -  Megakaryocytes and thrombopoiesis

    <!--list-separator-->

    -  Other myeloid cells

    <!--list-separator-->

    -  Cytologic abnormalities in myeloid cells in hematologically normal subjects

<!--list-separator-->

-  Bone marrow lymphoid cells

<!--list-separator-->

-  Other cells present in normal bone marrow

    <!--list-separator-->

    -  Normal bone marrow components

    <!--list-separator-->

    -  Extraneous cells and tissues

<!--list-separator-->

-  Cytochemistry and histochemistry

    <!--list-separator-->

    -  Cytochemistry

    <!--list-separator-->

    -  Histochemistry

    <!--list-separator-->

    -  Immunophenotyping including immunohistochemistry

<!--list-separator-->

-  Conclusion


### 11. Evaluation of anemia, leukopenia, and thrombocytopenia {#11-dot-evaluation-of-anemia-leukopenia-and-thrombocytopenia}


### 12. Bone marrow findings in inflammatory, infectious, and metabolic disorders {#12-dot-bone-marrow-findings-in-inflammatory-infectious-and-metabolic-disorders}


## III. Lymphoid neoplasms {#iii-dot-lymphoid-neoplasms}


### 13. Principles of classification of lymphoid neoplasms {#13-dot-principles-of-classification-of-lymphoid-neoplasms}

<!--list-separator-->

-  Historical background

<!--list-separator-->

-  Early events in lymphoid neoplasia: borderlands of malignancy

<!--list-separator-->

-  Small B-cell neoplasms

<!--list-separator-->

-  Aggressive B-cell lymphomas and borderline malignancies

<!--list-separator-->

-  Peripheral T-cell lymphomas

<!--list-separator-->

-  Histiocytic and dendritic cell neoplasms

<!--list-separator-->

-  Conclusion


### S1. Mature B-cell neoplasms {#s1-dot-mature-b-cell-neoplasms}

<!--list-separator-->

-  14. B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma, Monoclonal B-cell lymphocytosis, and B-cell prolymphocytic leukemia

<!--list-separator-->

-  15. Lymphoplasmacytic lymphoma and Waldenstrom macroglobulinemia

    <!--list-separator-->

    -  Definition of disease

        <!--list-separator-->

        -  LPL: small B-cell neoplasm composed of lymphocytes, plasma cells, and plasmacytoid lymphocytes, which does not meet criteria for any of the other small B-cell lymphomas that exhibits plasmacytic differentiation

    <!--list-separator-->

    -  Epidemiology and incidence

    <!--list-separator-->

    -  Clinical features

    <!--list-separator-->

    -  Morphology

        <!--list-separator-->

        -  Peripheral blood and bone marrow

        <!--list-separator-->

        -  Lymph nodes

        <!--list-separator-->

        -  Spleen and other tissues

    <!--list-separator-->

    -  Immunophenotype

    <!--list-separator-->

    -  Genetic features

        <!--list-separator-->

        -  MYD88 L265P mutation

        <!--list-separator-->

        -  Other somatic mutations

        <!--list-separator-->

        -  Cytogenetic abnormalities

    <!--list-separator-->

    -  Postulated normal counterpart and pathogenesis

    <!--list-separator-->

    -  Clinical course, treatment and prognosis

    <!--list-separator-->

    -  Differential diagnosis

        <!--list-separator-->

        -  Neoplastic conditions

        <!--list-separator-->

        -  IgM-secreting disorders

        <!--list-separator-->

        -  Other conditions

<!--list-separator-->

-  16. Hairy cell leukemia

<!--list-separator-->

-  17. Splenic marginal-zone lymphoma and other small B-cell neoplasms in the spleen

<!--list-separator-->

-  18. Follicular lymphoma (~13.7% of lymphomas)

<!--list-separator-->

-  19. Extranodal marginal zone lymphoma: MALT lymphoma

<!--list-separator-->

-  20. Primary cutaneous B-cell lymphomas

<!--list-separator-->

-  21. Nodal marginal zone lymphoma

<!--list-separator-->

-  22. Mantle cell lymphoma

<!--list-separator-->

-  23. Diffuse large B-cell lymphoma (~19.3% of lymphomas, 414-444)

    <!--list-separator-->

    -  Overview

        <!--list-separator-->

        -  Agressive

        <!--list-separator-->

        -  Curable in a large portion of patients who achieve remission

        <!--list-separator-->

        -  Previously there were two subtypes that were merged due to low intra\* and inter-observer reproducibility

    <!--list-separator-->

    -  Definition

        <!--list-separator-->

        -  Diffuse proliferation of large or medium-sized neoplastic B cells with a nuclear size greater than or equal to that of a histiocyte nucleus, or more than twice the size of a small lymphocyte

    <!--list-separator-->

    -  Epidemiology

        <!--list-separator-->

        -  Most common type of NHL (~31%)

        <!--list-separator-->

        -  No clear ethnic bias

            <!--list-separator-->

            -  Appears to be more DLBCL than Follicular lymphoma in Asians

        <!--list-separator-->

        -  Median age is 64 years

        <!--list-separator-->

        -  Slight male predominance 1.2:1

    <!--list-separator-->

    -  Etiology

        <!--list-separator-->

        -  Unclear in most patients

        <!--list-separator-->

        -  Minority occurs in setting of congenital immunodeficiency or acquired immunodeficiency such as HIV, transplant, history of methotrexate treatment for rheumatoid arthritis, fludarabine treatment for low-grade B-cell lymphoma

            <!--list-separator-->

            -  Commonly associated with Epstein-Barr virus (EBC) positivity

        <!--list-separator-->

        -  Angioimmunoblastic T-cell lymphoma

        <!--list-separator-->

        -  Rare extranodal cases association with chronic inflammation or irritation

        <!--list-separator-->

        -  Transformation from underlying low-grade lymphoma

    <!--list-separator-->

    -  Clinical features

        <!--list-separator-->

        -  Rapidly enlarging lymph nodes or tumor masses in extranodal sites

        <!--list-separator-->

        -  Extranodal involvement

            <!--list-separator-->

            -  71% have extranodal involvement during course of disease

            <!--list-separator-->

            -  30% present with extranodal involvement

            <!--list-separator-->

            -  Common sites include the GI tract (esp stomach) and Waldeyer's ring

        <!--list-separator-->

        -  Half with stage I or II (early); III (13%); IV(33%)

        <!--list-separator-->

        -  One-third have B symptoms

        <!--list-separator-->

        -  16% have bone marrow involvement, which includes cases with concordant and discordant bone marrow histology

    <!--list-separator-->

    -  Morphology

        <!--list-separator-->

        -

    <!--list-separator-->

    -  Immunophenotype

        <!--list-separator-->

        -  Pan B-cell markers (CD20, CD22, CD79a, PAX5)

        <!--list-separator-->

        -  Positive for surface or cytoplasmic immunoglobulin

        <!--list-separator-->

        -  BCL6+ in about 60%

        <!--list-separator-->

        -

    <!--list-separator-->

    -  Genetics

        <!--list-separator-->

        -  Clonally rearranged immunoglobulin heavy-chain and light-chain genes (IGH, IGK, and IGL) and germline T-cell receptor genes.

        <!--list-separator-->

        -  Hypermutated IGHV

        <!--list-separator-->

        -  Transformation pathway

            <!--list-separator-->

            -  20% of cases show t(14; 18)(q32; q21) BCL2 rearrangement, which is considered a hallmark of follicular lymphoma

            <!--list-separator-->

            -  Such cases may have transformed from a known or occult follicular lymphoma

        <!--list-separator-->

        -  De novo pathway

            <!--list-separator-->

            -  30% show BCL6 3q27 rearrangement, but is also found in some follicular lymphomas

                <!--list-separator-->

                -  Most commonly the translocation partner involves the immunoglobulin genes via t(3;14)(q27; q32)

            <!--list-separator-->

            -  73% show BCL6 somatic mutation and is unrelated to the presence or absence of BCL6 rearrangement

                <!--list-separator-->

                -  This is a marker for cells that have been through the germinal center and is thereby also observed in

        <!--list-separator-->

        -  Myc 8q24 rearrangement occurs in about 10% of DLBCLs being more common in HIV infected patients, pediatric patients, and extranodal lymphomas

            <!--list-separator-->

            -  40-60% of cases with Myc rearrangment represent double or triple-hit lymphoma with co-existing BCL2 and/or BCL6 rearrangement and such cases are reclassified as high-grade B-cell lymphoma with BCL2 and/or BCL6 and Myc rearrangement in the 2016 WHO classification

            <!--list-separator-->

            -  Double-hit

    <!--list-separator-->

    -  Molecular subtypes

        <!--list-separator-->

        -  Germinal-center B-cell type

        <!--list-separator-->

        -  Activated B-cell type

    <!--list-separator-->

    -  Postulated cell of origin

    <!--list-separator-->

    -  Clinical course

    <!--list-separator-->

    -  Prognostic factors

    <!--list-separator-->

    -  Differential diagnosis

    <!--list-separator-->

    -  Other lymphomas of large B-cells

        <!--list-separator-->

        -  T-cell/Histiocyte-rich large B-cell lymphoma

        <!--list-separator-->

        -  Primary mediastinal (thymic) large B-cell lymphoma

        <!--list-separator-->

        -  Intravascular large B-cell lymphoma

<!--list-separator-->

-  24. Burkitt's lymphoma and its mimics

<!--list-separator-->

-  25. Plasmablastic neoplasms other than plasma cell myeloma

<!--list-separator-->

-  26. Plasma cell neoplasms

    <!--list-separator-->

    -  Plasma cell neoplasms

        <!--list-separator-->

        -  Definition

            <!--list-separator-->

            -  Clonal proliferations of Ig-producing plasma cells or lymphocytes that make and secrete a single class of Ig or a polypeptide subunit of a single Ig detectable as a so-called monoclonal protein (M-protein) on serum or urine protein electrophoresis

        <!--list-separator-->

        -  Classification

    <!--list-separator-->

    -  Plasma cell myeloma

        <!--list-separator-->

        -  Definition

            <!--list-separator-->

            -  Bone marrow-based, multifocal plasma cell neoplasm associated with an M-protein in serum or urine. Other organs may be secondarily involved.

        <!--list-separator-->

        -  Diagnostic criteria

        <!--list-separator-->

        -  Epidemiology

        <!--list-separator-->

        -  Etiology and pathogenesis

        <!--list-separator-->

        -  Clinical features

        <!--list-separator-->

        -  Laboratory findings

        <!--list-separator-->

        -  Radiographic studies

        <!--list-separator-->

        -  Blood smear and bone marrow findings

        <!--list-separator-->

        -  Histopathology

        <!--list-separator-->

        -  Plasma cell myeloma clinical variants

        <!--list-separator-->

        -  Non-secretory plasma cell myeloma

        <!--list-separator-->

        -  Smoldering plasma cell myeloma (asymptomatic myeloma)

        <!--list-separator-->

        -  Plasma cell leukemia

        <!--list-separator-->

        -  Immunophenotype ([flow cytometry]({{< relref "flow_cytometry" >}}))

        <!--list-separator-->

        -  Immunophenotypic features of normal and neoplastic plasma cells

        <!--list-separator-->

        -  Technical issues

        <!--list-separator-->

        -  Diagnostic issues

        <!--list-separator-->

        -  Unusual morphologic variants of myeloma

        <!--list-separator-->

        -  Florid reactive plasmacytosis

        <!--list-separator-->

        -  Non-Hodgkin's lymphomas with extreme plasma cell differentiation

        <!--list-separator-->

        -  Prediction of genetic abnormalities

        <!--list-separator-->

        -  Prognostic issues

        <!--list-separator-->

        -  Quantitative issues at diagnosis

        <!--list-separator-->

        -  Minimal residual disease

        <!--list-separator-->

        -  Circulation plasma cells

        <!--list-separator-->

        -  Immunophenotype

        <!--list-separator-->

        -  Genetics

        <!--list-separator-->

        -  Genetic testing for plasma cell myeloma

        <!--list-separator-->

        -  Differential diagnosis

        <!--list-separator-->

        -  Treatment and prognosis

    <!--list-separator-->

    -  Monoclonal gammopathy of undetermined significance

        <!--list-separator-->

        -  Definition

        <!--list-separator-->

        -  Epidemiology and etiology

        <!--list-separator-->

        -  Clinical and laboratory features

        <!--list-separator-->

        -  Blood and bone marrow findings

        <!--list-separator-->

        -  Immunophenotype

        <!--list-separator-->

        -  Genetics

        <!--list-separator-->

        -  Differential diagnosis

        <!--list-separator-->

        -  Clinical course, treatment, and prognostic factors

    <!--list-separator-->

    -  Plasmacytoma

        <!--list-separator-->

        -  Solitary plasmacytoma of bone

        <!--list-separator-->

        -  Extraosseous plasmacytoma

    <!--list-separator-->

    -  Immunoglobulin deposition diseases

        <!--list-separator-->

        -  Primary amyloidosis

        <!--list-separator-->

        -  Systemic light chain and heavy chain deposition diseases

    <!--list-separator-->

    -  Plasma cell neoplasms with associated paraneoplastic syndrome

        <!--list-separator-->

        -  POEMS syndrome (osteosclerotic myeloma)

        <!--list-separator-->

        -  TEMPI syndrome

<!--list-separator-->

-  27. Nodular lymphocyte--predominant Hodgkin's

<!--list-separator-->

-  28. Classical Hodgkin's lymphoma and related lesions

<!--list-separator-->

-  29. Virally associated B-cell lymphoproliferative disease


### S2. Mature T-cell and NK-cell neoplasms {#s2-dot-mature-t-cell-and-nk-cell-neoplasms}

<!--list-separator-->

-  30. Virally associated T-cell and NK-cell neoplasms

<!--list-separator-->

-  31. T-cell and NK-cell large granular lymphocyte proliferations

<!--list-separator-->

-  32. T-cell prolymphocytic leukemia

<!--list-separator-->

-  33. Adult T-cell leukemia/lymphoma

<!--list-separator-->

-  34. Hepatosplenic T-cell lymphoma

<!--list-separator-->

-  35. Peripheral T-cell lymphoma, not otherwise specified (NOS)

<!--list-separator-->

-  36. Angioimmunoblastic T-cell lymphoma

<!--list-separator-->

-  37. Anaplastic large cell lymphoma, ALK positive and ALK negative

<!--list-separator-->

-  38. Enteropathy-associated T-cell lymphoma and other primary intestinal T-cell lymphomas

<!--list-separator-->

-  39. Mycosis fungoides and Sezary syndrome

<!--list-separator-->

-  40. Primary cutaneous CD30-Positive T-cell lymphoproliferative disorders

<!--list-separator-->

-  41. Primary cutaneous T-cell lymphomas: rare subtypes


### S3. Precursor B\* and T-cell neoplasms {#s3-dot-precursor-b-and-t-cell-neoplasms}

<!--list-separator-->

-  42. Precursor B\* and T-cell neoplasms

    <!--list-separator-->

    -  42.1 Classification of precursor lymphoid neoplasms

        <!--list-separator-->

        -  The majority of ALLs are derived from precursor B cells

        <!--list-separator-->

        -  The majority of LBLs possess a precursor T-cell phenotype

    <!--list-separator-->

    -  42.2 B-cell lymhoblastic leukemia/lymhoblastic lymphoma

        <!--list-separator-->

        -  Definition

            <!--list-separator-->

            -  Clonal disorder of hematopoietic precursors with evidence of early B-cell differentiation

            <!--list-separator-->

            -  More than 95% express CD19, HLA-DR, and rearrangement of IgH locus

        <!--list-separator-->

        -  Epidemiology

            <!--list-separator-->

            -  ALL is most common malignancy of children (80% of childhood leukemias) in children <6 years old

            <!--list-separator-->

            -  20% of adult leukemias

        <!--list-separator-->

        -  Etiology

            <!--list-separator-->

            -

        <!--list-separator-->

        -  Clinical features

        <!--list-separator-->

        -  Morphology

        <!--list-separator-->

        -  Immunophenotype

        <!--list-separator-->

        -  Genetics and molecular findings

        <!--list-separator-->

        -  Normal counterpart

        <!--list-separator-->

        -  Clinical course

        <!--list-separator-->

        -  Differential diagnosis

    <!--list-separator-->

    -  42.3 T-cell lymphoblastic leukemia/lymhoblastic lymphoma

        <!--list-separator-->

        -  Definition

        <!--list-separator-->

        -  Epidemiology

        <!--list-separator-->

        -  Etiology

        <!--list-separator-->

        -  Clinical features

        <!--list-separator-->

        -  Morphology

        <!--list-separator-->

        -  Immunophenotype

        <!--list-separator-->

        -  Genetics and molecular findings

        <!--list-separator-->

        -  Normal counterpart

        <!--list-separator-->

        -  Clinical course

        <!--list-separator-->

        -  Differential diagnosis

<!--list-separator-->

-  43. Acute leukemias of ambiguous lineage


## IV. Myeloid neoplasms {#iv-dot-myeloid-neoplasms}


### 44. Principles of classification of myeloid neoplasms {#44-dot-principles-of-classification-of-myeloid-neoplasms}


### 45. Myelodysplastic syndromes {#45-dot-myelodysplastic-syndromes}


### 46. Acute myeloid leukemia {#46-dot-acute-myeloid-leukemia}


### 47. Myeloproliferative neoplasms {#47-dot-myeloproliferative-neoplasms}


### 48. Myelodysplastic/Myeloproliferative neoplasms {#48-dot-myelodysplastic-myeloproliferative-neoplasms}


### 49. Mastocytosis {#49-dot-mastocytosis}


### 50. Eosinophilia and chronic eosinophilic leukemia, including myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRA, PDGFRB, FGFR1, or JAK2 {#50-dot-eosinophilia-and-chronic-eosinophilic-leukemia-including-myeloid-lymphoid-neoplasms-with-eosinophilia-and-rearrangement-of-pdgfra-pdgfrb-fgfr1-or-jak2}


### 51. Blastic plasmacytoid dendritic cell neoplasm {#51-dot-blastic-plasmacytoid-dendritic-cell-neoplasm}


## V. Histiocytic proliferations {#v-dot-histiocytic-proliferations}


### 52. Non-neoplastic histiocytic proliferations of lymph nodes and bone marrow {#52-dot-non-neoplastic-histiocytic-proliferations-of-lymph-nodes-and-bone-marrow}


### 53. Histiocytic and dendritic cell neoplasms including Langerhans cell histiocytosis and Langerhans cell sarcoma {#53-dot-histiocytic-and-dendritic-cell-neoplasms-including-langerhans-cell-histiocytosis-and-langerhans-cell-sarcoma}


## VI. Immunodeficiency disorders {#vi-dot-immunodeficiency-disorders}


### 54. The pathology of primary immunodeficiencies {#54-dot-the-pathology-of-primary-immunodeficiencies}


### 55. Iatrogenic immunodeficiency-associated lymphoproliferative disorders {#55-dot-iatrogenic-immunodeficiency-associated-lymphoproliferative-disorders}


## VII. Site-specific issues in the diagnosis of lymphoma and leukemia {#vii-dot-site-specific-issues-in-the-diagnosis-of-lymphoma-and-leukemia}


### 56. Bone marrow evaluation for lymphoma {#56-dot-bone-marrow-evaluation-for-lymphoma}


### 57. Evaluation of the bone marrow after therapy {#57-dot-evaluation-of-the-bone-marrow-after-therapy}


### 58. Non-hematopoietic neoplasms of the bone marrow {#58-dot-non-hematopoietic-neoplasms-of-the-bone-marrow}


### 59. Non-lymphoid lesions of the lymph nodes {#59-dot-non-lymphoid-lesions-of-the-lymph-nodes}


### 60. Spleen: normal architecture and neoplastic and non-neoplastic lesions {#60-dot-spleen-normal-architecture-and-neoplastic-and-non-neoplastic-lesions}


### 61. Diagnosis of lymphoma in extranodal sites other than skin {#61-dot-diagnosis-of-lymphoma-in-extranodal-sites-other-than-skin}
